The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Sorokin M.Yu.
Bekhterev National Research Center for Psychiatry and Neurology
Kasyanov E.D.
Bekhterev National Medical Research Center for Psychiatry and Neurology
Mazo G.E.
Bekhterev National Medical Research Center for Psychiatry and Neurology
Tsapko D.S.
Sechenov First Moscow State Medical University
Low doses of quetiapine (Seroquel) as an impulsivity corrector in patients with bipolar affective disorder in remission
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(8): 120‑127
Views: 9627
Downloaded: 261
To cite this article:
Morozova MA, Potanin SS, Burminsky DS, et al. . Low doses of quetiapine (Seroquel) as an impulsivity corrector in patients with bipolar affective disorder in remission. S.S. Korsakov Journal of Neurology and Psychiatry.
2022;122(8):120‑127. (In Russ.)
https://doi.org/10.17116/jnevro2022122081120
To evaluate the effectiveness of low doses (25-75 mg/day) of quetiapine (Seroquel) in patients with bipolar affective disorders in a euthymic state with signs of impaired impulse control.
The main criteria for patients’ selection were as follows: both sex, diagnoses of bipolar affective disorders, remission (euthymic state), adult age (from 18 to 60 years old), stable basic therapy. The duration of the study was 6 weeks, a dose of quetiapine (Seroquel) varied from 25 to 75 mg. The examinations were carried out with the Barratt scale, computerized Go-No-Go and Balloon tests.
The study group included 32 patients (11 men and 21 women), mean age 31.2±9.7 years (minimum 18, maximum 60 years). The changes in Barratt total score (p=0.000014, Wilcoxon test, effect size 0.48) and Balloon total earnings (p=0.03, Wilcoxon test, effect size 0.22) were statistically significant and reflected clinically significant improvement. The changes of the indices of the Go-No-Go test were not significant. The data of fMRI showed an increase in the connectivity of the cortex of the central and parietal tegmentum of the left hemisphere with other areas of the brain, which correlated with the changes in psychometric and test parameters.
The results of the study showed that add-on of the low doses of quetiapine (Seroquel) significantly decreases impaired impulse control in remitted patients with bipolar affective disorders both in self-evaluation and in risk-taking experimental test. The drop of high level of impulsivity can improve the quality and stability of remission and reduce behavioral risks due to impaired impulse control.
Keywords:
Authors:
Sorokin M.Yu.
Bekhterev National Research Center for Psychiatry and Neurology
Kasyanov E.D.
Bekhterev National Medical Research Center for Psychiatry and Neurology
Mazo G.E.
Bekhterev National Medical Research Center for Psychiatry and Neurology
Tsapko D.S.
Sechenov First Moscow State Medical University
Received:
10.06.2022
Accepted:
21.06.2022
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.